17th Feb 2015 07:50
LONDON (Alliance News) - Lifeline Scientific PLC on Tuesday said it expects revenue for 2014 to be ahead of market expectations on the back of a strong second half performance.
The medical technology company, which makes transplantation technology, said the second half of the year to the end of December was positive, boosted by growing market adoption of its products and positive clinical evidence in support of its lead offerings.
The group saw a strong performance in North America and significant orders in China for the LifePort Kidney Transporter and related portfolio of products.
The group expects to post revenue for 2014 of around USD35.2 million, up from USD33.2 million in 2013 and ahead of market expectations.
In addition, the group expects its operating profit for the year, adjusted for non-recurring items, to be ahead of market expectations and therefore above USD2.2 million.
The company will post its full-year results on April 27.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
LSIC.L